Ibex Wealth Advisors Avadel Pharmaceuticals PLC Transaction History

Ibex Wealth Advisors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 22, 2022	SELL	$7.34 - $11.18 $11,010 - $16,770	-1,500 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$6.49 - $9.91 $9,735 - $14,865	1,500 New	1,500 $15,000
Q3 2019 Nov 12, 2019	SELL	$1.92 - $4.47 $2,880 - $6,705	-1,500 Closed	0 $0
Q2 2019 Jul 30, 2019	BUY	$1.09 - $3.19 $1,635 - $4,785	1,500 New	1,500 $4,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Ibex Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Ibex Wealth Advisors with notifications on news.